FDA declares end to Wegovy and Ozempic shortage

The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The FDA's announcement comes months after drugmaker Novo Nordisk told the agency that all dosages of its semaglutide product had become fully available nationwide. The company said in a statement that it confirms the supply of the medications, which are prescription-only, "now meets or exceeds both current and projected U.S. demand."